Validation of an integrated series of ligand-binding assays for the quantitative determination of antibody-drug conjugates in biological matrices

Bioanalysis

Volumn 8, Issue 6, 2016, Pages 519-531

  Myler, Heather ^a   Rangan, Vangipuram S ^b   Kozhich, Alex ^a   Hoffpauir, Brian ^c   Dail, Donna ^a   Cummings, Jennifer ^a   Saewert, Mark ^a   Manney, Amy ^a   Liu, Ang ^a   Rao, Chetana ^b   Wang, Jian ^a   Pillutla, Renuka ^a   DeSilva, Binodh ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Biologics Discovery California   (United States)

^c Pharmaceutical Product Development   (United States)

Author keywords

antibody drug conjugate; drug antibody ratio; ligand binding assays; payload; selectivity; specificity; total antibody

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; UNCLASSIFIED DRUG; DRUG; LIGNAN; MONOCLONAL ANTIBODY;

ANALYTIC METHOD; ANIMAL TISSUE; ARTICLE; BIOLOGICAL MATRIX; CONTROLLED STUDY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; MEASUREMENT ACCURACY; MEASUREMENT ERROR; MEASUREMENT PRECISION; MICROFLUIDIC ANALYSIS; NONHUMAN; QUANTITATIVE ANALYSIS; RECEPTOR BINDING ASSAY; TISSUES; VALIDATION PROCESS; CHEMISTRY; HALF LIFE TIME; IMMUNOASSAY; QUALITY CONTROL; STANDARDS; VALIDATION STUDY;

ANTIBODIES, MONOCLONAL; HALF-LIFE; IMMUNOASSAY; IMMUNOCONJUGATES; LIGNANS; PHARMACEUTICAL PREPARATIONS; QUALITY CONTROL;

EID: 84960431659     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.16.13     Document Type: Article

References (20)

1. Diamantis N, Banerji U. Antibody-drug conjugates - an emerging class of cancer treatment. Br. J. Cancer doi: 10.1038/bjc.2015.435 (2016) (Epub ahead of print).
2. Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci. Rep. 35(4), 1-20 (2015).
3. Perez HL, Cardarelli PM, Deshpande S et al. Antibody- drug conjugates: current status and future directions. Drug Discov. Today 19(7), 869-881 (2014).
4. DeSilva B, Smith W, Weiner R et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20, 1885-1900 (2003).
5. Myler HA, Given A, Kolz K et al. Biotherapeutic bioanalysis: a multi-indication case study review. Bioanalysis 3(6), 623-643 (2011).
6. Kaur S, Xu K, Saad OM et al. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis 5(2), 201-226 (2013).
7. Gorovits B, Alley SC, Bilic S et al. 2011 Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis 5(9), 997-1006 (2013).
8. Hamblett KJ, Senter PD, Chace DF et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10(20), 7063-7070 (2004).
9. Lee JW, Kelley M, King LE et al. Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J. 13(1), 99-110 (2011).
10. Cho H, Daniel T, Buechler YJ et al. Optimized clinical performance of growth hormone with an expanded genetic code. Proc. Natl Acad. Sci. USA 108(22), 9060-9065 (2011).
11. Sukumaran S, Gadkar K, Zhang C et al. Mechanismbased pharmacokinetic/pharmacodynamic model for THIOMAB™ drug conjugates. Pharm. Res. 32(6), 1884-1893 (2014).
12. Myler H, Rangan V, Wang J et al. An integrated multiplatform bioanalytical strategy for antibody-drug conjugates: a novel case study. Bioanalysis 7(13), 1569-1582 (2015).
13. Liu A, Kozhich A, Passmore D et al. Quantitative bioanalysis of antibody-conjugated payload in monkeyplasma using a hybrid immuno-capture LC-MS/MS approach: assay development, validation, and a case study. J. Chromatogr. B 1002, 54-62 (2015).
14. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Bioanalytical Method Validation. Rockville, MD (2013). www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ ucm368107.pdf
15. European Medicines Agency. Guideline on Bioanalytical Method Validation. London, England (2011). www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2011/08/WC500109686.pdf
16. Japan Ministry of Health and Labor Welfare. Guideline on Bioanalytical Method (Ligand Binding Assay) Validation in Pharmaceutical Development (2014). www.nihs.go.jp/drug/BMV/BMV-LBA-draft-140124-E- rev.pdf
17. China Pharmacopoeia (ChP). Draft Guidance on Bioanalytical Method Validation (2014). http://knex2014.europeanbioanalysisforum.eu/site/ ebf-knex2014/assets/slides/Dafang-Zhong--Guidelines-on- BMV-in-China.pdf
18. Sailstad JM, Amaravadi L, Clements-Egan A et al. A white paper-consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements. AAPS J. 16(3), 488-498 (2014).
19. Gibiansky L, Gibiansky E. Target-mediated drug disposition model and its approximations for antibody-drug conjugates. J. Pharmacokinet. Pharmacodyn. 41, 35-47 (2014).
20. Lu D, Gibiansky L, Jin JY et al. Integrated pharmacokinetic model for antibody-drug-conjugate (ADC) in patients with B-cell malignancy: implications for optimal sampling. J. Pharmacokinet. Pharmacodyn. 41, S44 (2014).